---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-027743"
form_type: "8-K"
ticker: "GLSI"
cik: "0001799788"
company_name: "Greenwich LifeSciences, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T10:08:39.660198+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Greenwich LifeSciences updates corporate presentation; highlights GP2 Phase IIb data and partnership discussions

## Summary
- Combined analysis of 5-year Phase IIb data shows no recurrences in HER2/neu 3+ patients receiving 6 primary injections (p=0.0338).
- Company reports interest from large pharma, regional pharma, and biotech investors regarding licensing and collaboration.
- Discussions include possible GP2 licensing, new investment banking partners, Phase III trial collaboration, and European expansion.
- GP2 treatment was well tolerated with no serious adverse events across 138 patients in 4 clinical trials.
- Phase III clinical trial planned with similar treatment regime to Phase IIb.

## SEC filing metadata
- accession: 0001493152-21-027743
- form_type: 8-K
- ticker: GLSI
- cik: 0001799788
- company_name: Greenwich LifeSciences, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799788/000149315221027743/0001493152-21-027743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799788/000149315221027743/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-027743
- JSON: https://secwatch.observer/filing/0001493152-21-027743.json
- Plain text: https://secwatch.observer/filing/0001493152-21-027743.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.